NEO100 for Meningioma

Overseen By Frances E. Chow

Age: Any Age

Sex: Any

Trial Phase: Phase 2

Sponsor: Neonc Technologies, Inc.

Must not be taking: Chemotherapy, Investigational agents

Disqualifiers: Pregnancy, Breastfeeding, Inadequate organ function, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 28-day cycles

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether NEO100, a treatment based on perillyl alcohol, can safely and effectively aid individuals with high-grade meningioma, a type of brain tumor unresponsive to surgery and radiation. Participants will self-administer the treatment four times daily in 28-day cycles until their condition changes. This study may suit those with high-grade meningioma that persists, grows, or recurs after previous treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Do I have to stop taking my current medications for the trial?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot take chemotherapy or investigational agents within 14 days of starting the study treatment. For prior systemic agents, you must wait at least 4 weeks (or 5 half-lives, whichever is shorter) before starting the trial. No concurrent investigational agents or meningioma-directed therapy is allowed during the study.

Is there any evidence suggesting that NEO100 is likely to be safe for humans?

Research has shown that NEO100, which contains perillyl alcohol, has been tested in people with brain tumors. In an earlier study, patients with glioma received NEO100 nasally. The treatment was well tolerated, meaning patients managed it without major problems. Additionally, there was a suggestion that it might help patients live longer compared to past data on similar patients.

While detailed safety information for NEO100 in meningioma is limited, the current phase of the clinical trial suggests that safety has been studied before. Trials at this stage typically indicate that earlier tests found the treatment safe enough. If considering joining a trial, discussing it with a doctor is advisable. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for meningioma?

NEO100 is unique because it is derived from perillyl alcohol, a compound found in essential oils of plants like peppermint and lavender. Unlike standard treatments for high-grade meningioma, which typically involve surgery and radiation, NEO100 is administered intranasally, allowing it to bypass the blood-brain barrier more effectively. Researchers are excited about NEO100 because it targets tumor cells directly with potentially fewer side effects, offering a new hope for patients with recurrent or progressive high-grade meningiomas.

What evidence suggests that NEO100 might be an effective treatment for high-grade meningioma?

Research has shown that NEO100, a type of perillyl alcohol, may help treat serious brain tumors called high-grade meningiomas. Studies have found that perillyl alcohol can stop cancer cells from growing in various tumors. In this trial, NEO100 is administered nasally, allowing it to reach brain tumors more directly. Early results suggest this method can slow tumor growth by quickly targeting the affected area. While more research is needed, this treatment's ability to target tumor cells offers hope for people with high-grade meningioma. ^{5 6 7 8 9}

Who Is on the Research Team?

Vincent F Simmon, PhD

Principal Investigator

NeOnc Technologies

Patrick Walters

Principal Investigator

NeOnc Technologies

Tom Chen, MD, PhD

Principal Investigator

NeOnc Technologies

Are You a Good Fit for This Trial?

This trial is for patients with high-grade meningioma that's come back or hasn't fully been removed by surgery. They should have a life expectancy of at least three months, be over 12 years old, and not have tumors larger than 30 mm or in multiple places. Participants need to be stable on steroids for five days before consent and agree to use contraception. Those who've had certain recent treatments or uncontrolled illnesses can't join.

Inclusion Criteria

Patient must have an expected survival of at least three months.

My meningioma is Grade II or III and has come back or gotten worse after surgery and radiation.

My organs and bone marrow are working well.

Exclusion Criteria

I have been treated with perillyl alcohol before.

I had a specific radiation treatment called brachytherapy less than 6 months ago.

My cancer has spread to the lining of my brain and spinal cord.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants self-administer NEO100 intranasally four times daily on a 28-day treatment cycle until disease progression, death, or withdrawal

28-day cycles

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

What Are the Treatments Tested in This Trial?

Interventions

• NEO100

Trial Overview The study tests NEO100 (perillyl alcohol) given four times daily over a 28-day cycle, up to twelve cycles unless the disease progresses or the patient passes away. Up to thirty patients will take part, aiming for twenty-nine evaluable participants. The trial checks how safe NEO100 is, how it moves through the body (pharmacokinetics), and its effectiveness against residual or recurring high-grade meningioma.

How Is the Trial Designed?

Group I: Patients with high-grade meningioma Experimental Treatment 1 Intervention

30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma

NEO100 is already approved in United States for the following indications:

Approved in United States as NEO100 for:

• High-grade meningioma
• Recurrent glioblastoma

Who Is Running the Clinical Trial?

Neonc Technologies, Inc.

Lead Sponsor

Trials

4

Recruited

230+

Published Research Related to This Trial

Perillyl alcohol (POH) has shown potential as an anticancer agent, particularly with an intra-nasal formulation that produced promising results in patients with malignant glioma, despite less success with oral formulations.

POH's unique ability to cross biological barriers, such as the blood-brain barrier, enhances its value in drug development, allowing for innovative delivery methods and combinations with other therapeutic agents to create new treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Chen, TC., da Fonseca, CO., Levin, D., et al.[2021]

Perillyl alcohol (POH) effectively inhibits the growth of both estrogen receptor-positive and negative breast cancer cell lines in a dose-dependent manner, primarily by causing cell cycle arrest in the G1 phase.

In a mouse model, POH significantly suppressed tumor growth and lymph node metastasis when administered at a dose of 75 mg/kg three times a week over a 6-week period, demonstrating its potential as a therapeutic agent against breast cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Yuri, T., Danbara, N., Tsujita-Kyutoku, M., et al.[2016]

Perillyl alcohol (POH), a natural compound, initially showed promise in inhibiting tumor growth in preclinical studies, but clinical trials using oral administration resulted in significant side effects like nausea and vomiting, leading to patient withdrawals.

Recent trials in Brazil using intranasal delivery of POH for patients with recurrent malignant gliomas demonstrated that this method is well tolerated and effective, reviving interest in POH as a potential cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Chen, TC., Fonseca, CO., Schönthal, AH.[2022]

Perillyl alcohol (POH) shows strong antitumor activity, but its effectiveness is limited by poor tolerance when taken orally, making intranasal delivery a promising alternative for targeting brain tumors.

The study developed a highly sensitive method for measuring perillic acid (PA), a metabolite of POH, in rat plasma and brain, demonstrating that chitosan nanoemulsions significantly enhance the bioavailability of POH, suggesting improved therapeutic potential for brain cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intranasal administration of perillyl alcohol-loaded nanoemulsion and pharmacokinetic study of its metabolite perillic acid in plasma and brain of rats using ultra-performance liquid chromatography/tandem mass spectrometry. da Silva Santos, J., Diedrich, C., Machado, CS., et al.[2021]

Intranasal delivery of NEO100, a pharmaceutical-grade version of perillyl alcohol, successfully resulted in the detection of both perillyl alcohol and its metabolite perillic acid in a patient's glioblastoma tumor tissue after over 3 years of treatment.

This study is the first to demonstrate that intranasal administration can effectively deliver therapeutic agents to brain tumors, suggesting that this noninvasive method could be a promising new treatment option for glioblastoma and potentially other brain-localized malignancies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case. Schönthal, AH., Swenson, S., Bonney, PA., et al.[2022]

In a study of 67 patients with recurrent malignant gliomas treated with intranasal perillyl alcohol, those with tumors located in the basal ganglia had significantly longer survival compared to those with lobar gliomas.

The presence of peritumoral brain edema (PTBE) was associated with poor therapeutic response and shorter survival, indicating that tumor size and edema may influence treatment outcomes and the behavior of glioma cells.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Da Fonseca, CO., Silva, JT., Lins, IR., et al.[2021]

S-(-)-Perillyl alcohol was successfully converted into a new metabolite, 1,2-dihydroxyperillyl alcohol, by the fungus Fusarium heterosporium over a 10-day period, indicating potential for biotransformation in drug development.

The conversion yielded 13% of the new metabolite, which was characterized using various spectroscopic methods, suggesting that this process could be useful for producing novel compounds with possible therapeutic applications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Microbial hydroxylation of S-(-)-perillyl alcohol by Fusarium heterosporium. Kiran, I.[2016]

Intranasal delivery of NEO100, a purified form of perillyl alcohol, was well tolerated in a Phase I trial with 12 patients suffering from recurrent glioblastoma, with no severe adverse events reported.

The treatment showed promising survival outcomes, with a 33% progression-free survival at 6 months and a 55% overall survival at 12 months, suggesting that this novel approach may be beneficial for patients with recurrent GBM.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Schönthal, AH., Peereboom, DM., Wagle, N., et al.[2022]

NEO100 significantly enhances the ability of trastuzumab to penetrate the blood-brain barrier (BBB), allowing for greater therapeutic activity against brain tumors in mouse models of HER2+ breast cancer.

When combined with NEO100, intravenous trastuzumab and the trastuzumab-drug conjugate T-DM1 resulted in improved overall survival for tumor-bearing mice, indicating a promising strategy for treating brain metastases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Wang, W., He, H., Marín-Ramos, NI., et al.[2022]

Perillyl alcohol (POH) is effective against both temozolomide-sensitive and temozolomide-resistant glioma cells, showing cytotoxic effects through mechanisms involving endoplasmic reticulum stress and inhibition of survival pathways.

Intranasal administration of POH was well tolerated and led to decreased tumor growth and increased survival in animal models with intracranial tumors, suggesting a promising route for treatment of resistant gliomas.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Cho, HY., Wang, W., Jhaveri, N., et al.[2021]

Citations

1. aging.networkofcare.org aging.networkofcare.org/sanmateo/CommunityResources/ClinicalTrials/Detail/NCT05023018?keyword=%22Meningioma%22

NEO100 and High-Grade Meningioma ... efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection ...

2. synapse.patsnap.com synapse.patsnap.com/drug/290968f178f5402cb9a255edf7daafb5

Perillyl alcohol - Drug Targets, Indications, Patents ... NEO100 in Participants with Residual, Progressive or Recurrent High-Grade Meningioma. 100 Clinical Results associated with Perillyl alcohol. Login to view more ...

3. scispace.com scispace.com/papers/intranasal-delivery-of-perillyl-alcohol-neo100-as-a-new-1j1bcq0y9y

Intranasal Delivery of Perillyl Alcohol (NEO100) as a New ... Intranasal Delivery of Perillyl Alcohol (NEO100) as a New Treatment Strategy for Glioma ; 10.1056/NEJMOA043330 · Roger Stupp, · 09 Mar 2005 ; 10.1016/S1470-2045(09) ...

4. researchgate.net researchgate.net/publication/340593738_Limonene_terpenoid_obstructs_human_bladder_cancer_cell_T24_cell_line_growth_by_inducing_cellular_apoptosis_caspase_activation_G2M_phase_cell_cycle_arrest_and_stops_cancer_metastasis

Limonene terpenoid obstructs human bladder cancer cell ... and perillyl alcohol. Cancer Lett 1995;91:169-75. 18. Manassero CA, Girotti ... These data indicate that positive OCT-4 expression may be involved in the ...

5. malacards.org malacards.org/card/skin_benign_neoplasm

Skin Benign Neoplasm Inhibition of UVB-induced skin tumor development by drinking green tea polyphenols is mediated through DNA repair and subsequent inhibition of inflammation.

6. clinicaltrials.gov clinicaltrials.gov/study/NCT05023018

NCT05023018 | NEO100 and High-Grade Meningioma A study revealed that H-Ras and K-Ras farnesylation were inhibited by perillyl alcohol. Ras activity is elevated in malignant central nervous system tumors.

7. connect.careboxhealth.com connect.careboxhealth.com/en-US/trial/listing/302116

NEO100 and High-Grade Meningioma - Carebox Connect This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT02704858

NCT02704858 | Safety and Efficacy Study in Recurrent or ... This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of ...

9. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7879254/

Phase I trial of intranasal NEO100, highly purified perillyl ... Intranasal glioma therapy with NEO100 was well tolerated. It correlated with improved survival when compared to historical controls.